TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ondine Biomedical, Inc. ( (GB:OBI) ) has shared an announcement.
Ondine Biomedical Inc. announced the issuance of 800,457 common shares to the Royal Columbian Hospital Foundation following the completion of patient enrollment in a groundbreaking ICU nasal photodisinfection trial using Steriwave. This share issuance marks a significant milestone in the trial, which aims to explore the feasibility of Steriwave as a nasal decolonization tool in intensive care settings, potentially impacting the company’s market position in the ICU infection prevention sector.
The most recent analyst rating on (GB:OBI) stock is a Buy with a £55.00 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.
More about Ondine Biomedical, Inc.
Ondine Biomedical Inc. is a Canadian life sciences company specializing in light-activated antimicrobial therapies, known as photodisinfection, for infection prevention and treatment. The company has a range of investigational products based on its proprietary technology, with approvals in several countries and ongoing trials for regulatory approval in the US.
Average Trading Volume: 166,062
Technical Sentiment Signal: Buy
Current Market Cap: £57.62M
For detailed information about OBI stock, go to TipRanks’ Stock Analysis page.